Clinico-epidemiological profile of patients with vitiligo: A retrospective study from a tertiary care center of North India

Mahajan, Vikram K.; Vashist, Sanket; Chauhan, Pushpinder S; Mehta, Karan; Sharma, Vikas; Sharma, Abha

doi:10.4103/idoj.idoj_124_18

Cited by 38 publications

(36 citation statements)

References 24 publications

(42 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The average age of first lesions onset in vitiligo patients ranges between 18 and 32 years [28,29,33], what is consistent with the experimental group as the average age in the study was 29.69 years.…”

Section: Statistical Analysis Of the Gene Expressionsupporting

confidence: 87%

Evaluation of polymorphisms and expression of PTPN22, NLRP1 and TYR genes in vitiligo patients

Męcińska-Jundziłł¹,

Tadrowski²,

Jundziłł³

et al. 2023

pdia

View full text Add to dashboard Cite

Introduction: Vitiligo is a pigmentary disorder associated with a selective loss of melanocytes in the skin, its appendages and mucous membranes. Aim: The aim of the study was to evaluate the association between the rs2476601 polymorphism of the PTPN22 gene, the rs2670660 and rs6502867 polymorphisms of the NLRP1 gene and the rs1847134 and rs1393350 polymorphisms of the TYR gene and vitiligo. Another aim was to compare the gene expression in lesional and symmetrically non-lesional skin of vitiligo patients and healthy controls. Material and methods: The experimental group consisted of 42 patients and the control group consisted of 38 healthy volunteers. The polymorphisms of the genes were assessed with PCR-RFLP technique and gene expression with qRT-PCR technique. Results: We found that the CT genotype of the PTPN22 rs2476601 polymorphism is more frequent in vitiligo patients, in the case of the NLRP1 rs2670660 polymorphism it was the AG genotype, in the NLRP1 rs6502867 polymorphism they were the CT and CC genotypes and in the TYR rs1393350 polymorphism it was the AG genotype. There was no association between vitiligo and the TYR rs1847134 polymorphism. We found statistically significant differences in gene expression in the lesional and symmetrical non-lesional skin of vitiligo patients compared to the control group. Conclusions: Our analysis showed genotypes predisposing to vitiligo. We found that the gene expression is different not only in lesional but also in non-lesional skin of vitiligo patients, what may change the approach to treatment of the disease.

show abstract

Section: Statistical Analysis Of the Gene Expressionsupporting

confidence: 87%

Evaluation of polymorphisms and expression of PTPN22, NLRP1 and TYR genes in vitiligo patients

Męcińska-Jundziłł¹,

Tadrowski²,

Jundziłł³

et al. 2023

pdia

View full text Add to dashboard Cite

show abstract

“…More than half (57.5%) of the participants were employed. A study from northern India by Mahajan et al (2019) found that the onset age of vitiligo ranged from 6 months to 82 years, with the majority of patients (71.3%) experiencing the condition before the age of 25 [ 20 ]. Another study by El-Husseiny et al (2021) also documented that the average onset age of vitiligo in children was 6.18 years, with a mean condition duration of 2.12 years [ 21 ].…”

Section: Discussionmentioning

confidence: 99%

Does the Saudi Population Have Sufficient Awareness of Vitiligo in Southwest Saudi Arabia? A Cross-Sectional Survey, 2022

Keraryi

Hakami

et al. 2022

Clinics and Practice

View full text Add to dashboard Cite

Background: Vitiligo is a common acquired hypopigmentation skin condition defined by an idiopathic, gradual, and restricted loss of melanin pigment from otherwise healthy-looking skin. The present study aims to evaluate the knowledge and perceptions of and attitudes toward vitiligo among the general population of Jazan Province, Saudi Arabia. Methods: An observational cross-sectional survey targeting adults of the Jazan region was conducted in 2022. The data were collected using an electronic questionnaire distributed through social media in the region. Statistical analysis was performed using the SPSS computer program. Knowledge and attitude scores were computed. Results: Most of the respondents (83.7%) had an adequate knowledge level of vitiligo, and almost half of the respondents (46.8%) had a positive attitude toward the disease. The majority of the respondents (84.5%) knew that vitiligo is not contagious. However, the majority of the participants (78.6%) did not know that vitiligo is an autoimmune disease. Most of the respondents (93.1%) do not avoid shaking hands with a vitiligo patient to prevent infection, accept food prepared by a vitiligo patient (69.4%), accept sharing a plate with a vitiligo patient (73.6%), and accept to be helped by a vitiligo patient (86.7%). However, about half of the participants (50.4%) refused to marry a person diagnosed with vitiligo. The knowledge of vitiligo in the study population was not correlated with any of the demographic characters, such as age, gender, education, or occupation (p > 0.05). The most important factors associated with good attitudes were male gender (COR = 1.92; 95% CI: 1.92–2.84; p = 0.001) and being aged over 50 years (COR = 3.06; 95% CI: 1.53–6.13; p = 0.002). Conclusions: The population in Jazan had a good level of knowledge of vitiligo and a positive attitude toward patients with vitiligo. Social media is the source of information for vitiligo for the majority of the study population. The good attitude toward patients with vitiligo was more prevalent in males and older people. More efforts are needed to improve the knowledge of and attitudes toward vitiligo.

show abstract

“…The specific pathology is not known but may be related to genetic, immunological, and neurological factors [2]. Multiple mechanisms involving autoimmunity, cytotoxicity, oxidationantioxidation, and neural factors have been implicated [3,4]. Vitiligo affects nearly 1%-2% people globally, with the highest incidence recorded in the Indian subcontinent, followed by Mexico and Japan [5].…”

Section: Introductionmentioning

confidence: 99%

Apremilast Add-On Benefits Over Conventional Drugs (ABCD) in Unstable Non-segmental Vitiligo: A 12-Week Single-Center Randomized Controlled Trial

Sharma¹,

Bhardwaj²,

Dwivedi³

et al. 2023

Cureus

View full text Add to dashboard Cite

BackgroundApremilast is an oral phosphodiesterase-4 enzyme inhibitor that modulates the immune system by increasing intracellular cyclic adenosine monophosphate levels and inhibiting inflammatory cytokines synthesis. We aimed to compare the efficacy and safety of add-on apremilast in combination therapy with standard treatment in patients with unstable, non-segmental vitiligo. MethodsThe study was a 12-week randomized, controlled, parallel-group, open-labeled trial. The control group received standard treatment (n=15), and the intervention group received 30 mg apremilast twice daily in addition to standard treatment (n= 16). Time to the first sign of re-pigmentation, halt in progression, and change in vitiligo area scoring index (VASI) score is the primary outcomes. Normality was assessed, and appropriate parametric and nonparametric tests were undertaken. ResultsThirty-seven participants were randomized into two groups, and analysis was done on thirty-one participants. Over the treatment duration of 12 weeks, the median time to observe the first sign of repigmentation was four weeks in the add-on apremilast group compared to seven weeks in the control group (p=0.018). The halt in progression was observed more in the add-on Apremilast group (93.75%) compared to the control group (66.66%) (p=0.08). The VASI score decreased by 1.24 in the add-on apremilast group and 0.05 in the control group (p= 0.754). Parameters including body surface area, dermatology life quality index, and body mass index reduced significantly, while the visual analog scale increased significantly in the addon apremilast group. However, results were comparable between groups. ConclusionsTreatment with add-on apremilast accelerated clinical improvement. It also reduced disease progression and improved the disease index among participants. However, add-on apremilast had a lower tolerability profile than the control group.

show abstract

Clinico-epidemiological profile of patients with vitiligo: A retrospective study from a tertiary care center of North India

Cited by 38 publications

References 24 publications

Evaluation of polymorphisms and expression of PTPN22, NLRP1 and TYR genes in vitiligo patients

Evaluation of polymorphisms and expression of PTPN22, NLRP1 and TYR genes in vitiligo patients

Does the Saudi Population Have Sufficient Awareness of Vitiligo in Southwest Saudi Arabia? A Cross-Sectional Survey, 2022

Apremilast Add-On Benefits Over Conventional Drugs (ABCD) in Unstable Non-segmental Vitiligo: A 12-Week Single-Center Randomized Controlled Trial

Contact Info

Product

Resources

About